Advanced Solid Cancers

Oncology
3
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Beacon Therapeutics
Beacon TherapeuticsMA - Cambridge
1 program
1
PRL3-ZUMABPhase 2/3Monoclonal Antibody1 trial
Active Trials
NCT07290088RecruitingEst. Feb 2026
Bristol Myers Squibb
2 programs
1
1
Cdc7-inhibitorPhase 1/22 trials
RapamunePhase 11 trial
Active Trials
NCT00337376Terminated23Est. Jul 2010
NCT00886782Terminated11Est. Aug 2010
NCT00838890Terminated11Est. Jan 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Beacon TherapeuticsPRL3-ZUMAB
Bristol Myers SquibbCdc7-inhibitor
Bristol Myers SquibbCdc7-inhibitor
Bristol Myers SquibbRapamune

Clinical Trials (4)

Total enrollment: 45 patients across 4 trials

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

Start: Jan 2023Est. completion: Feb 2026
Phase 2/3Recruiting

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Start: May 2009Est. completion: Aug 201011 patients
Phase 1/2Terminated

A Study of BMS-863233 in Patients With Hematologic Cancer

Start: Mar 2009Est. completion: Jan 201011 patients
Phase 1/2Terminated

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Start: Feb 2006Est. completion: Jul 201023 patients
Phase 1Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 45 patients
2 companies competing in this space